StockDriftsStockDriftsTop 49 Tekla Capital Management Llc Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 5.36% | 616.5K | $136.9M | +10.90%(+60.60K) | — | 2023-06-30 | |
| JNJ | Johnson & Johnson | 4.68% | 721.8K | $119.5M | +0.00%(+0) | — | 2023-06-30 | |
| GILD | Gilead Sciences, Inc. | 4.63% | 1.53M | $118.2M | -1.67%(-26.00K) | — | 2023-06-30 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 4.54% | 161.4K | $116.0M | +12.84%(+18.36K) | — | 2023-06-30 | |
| VRTX | Vertex Pharmaceuticals Inc. | 4.38% | 318.0K | $111.9M | -3.72%(-12.30K) | — | 2023-06-30 | |
| LLY | Eli Lilly and Company | 3.92% | 213.4K | $100.1M | -26.15%(-75.56K) | — | 2023-06-30 | |
| UNH | Unitedhealth Group Inc. | 3.89% | 207.0K | $99.5M | -11.62%(-27.21K) | — | 2023-06-30 | |
| MRK | Merck & Co., Inc. | 3.29% | 728.2K | $84.0M | +31.88%(+176.03K) | — | 2023-06-30 | |
| ABBV | AbbVie Inc. | 2.88% | 545.6K | $73.5M | +6.65%(+34.03K) | — | 2023-06-30 | |
| BIIB | Biogen Inc. | 2.76% | 247.9K | $70.6M | +2.91%(+7.02K) | — | 2023-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — |
| Top 20 Holdings Unweighted | — | — | — | — |
Tekla Capital Management Llc reports $2.56B in US-listed equity holdings across 166 positions in its most recent 13F filing. Its largest disclosed positions are AMGN (5.4%), JNJ (4.7%) and GILD (4.6%). Figures reflect the Q2 2023 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Tekla Capital Management Llc, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Tekla Capital Management Llc’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1300336). View Tekla Capital Management Llc’s 13F filings on SEC